Study	I^2		Odds Ratio (95% CrI)
Afatinib_Cetuximab vs Afatinib			
29			1.0 (0.33, 3.2)
Pooled (pair−wise)			1.0 (0.20, 5.3)
Indirect (back−calculated)			NA
Pooled (network)			1.0 (0.25, 4.1)
Chemotherapy vs Afatinib			
50			1.3 (0.34, 5.1)
57			3.9e+10 (3.3e−05, 4.5e+25)
Pooled (pair−wise)	52.6%		2.0 (0.40, 11.)
Indirect (back−calculated)			0.92 (0.37, 2.3)
Pooled (network)	4.8%		1.1 (0.50, 2.5)
Erlotinib vs Afatinib			
38			1.0 (0.49, 2.0)
Pooled (pair−wise)			0.99 (0.24, 4.1)
Indirect (back−calculated)			0.78 (0.33, 1.8)
Pooled (network)	0.0%		0.83 (0.40, 1.7)
Gefitinib vs Afatinib			
48			0.50 (0.19, 1.3)
Pooled (pair−wise)			0.51 (0.10, 2.3)
Indirect (back−calculated)			0.63 (0.25, 1.6)
Pooled (network)	0.0%		0.59 (0.26, 1.3)
Placebo vs Afatinib			
54			0.24 (0.044, 1.3)
Pooled (pair−wise)			0.26 (0.027, 1.6)
Indirect (back−calculated)			0.74 (0.30, 1.8)
Pooled (network)	28.9%		0.62 (0.27, 1.4)

0.03   1   30

Study	I^2		Odds Ratio (95% CrI)

Gefitinib vs Almonertinib

4		←————————→	1.4e−18 (2.6e−43, 7.4e+06)
Pooled (pair−wise)		→	8.0e−14 (7.0e−31, 0.016)
Indirect (back−calculated)			NA
Pooled (network)		<	1.7e−11 (7.1e−37, 0.037)

Lazertinib vs Amivantamab_Lazertinib

r1		—o—	0.20 (0.12, 0.34)
Pooled (pair−wise)		—■—	0.20 (0.054, 0.76)
Indirect (back−calculated)			NA
Pooled (network)		—■—	0.21 (0.081, 0.53)

Osimertinib vs Amivantamab_Lazertinib

r1		—o—	0.16 (0.10, 0.23)
Pooled (pair−wise)		—■—	0.16 (0.043, 0.57)
Indirect (back−calculated)			NA
Pooled (network)		—■—	0.15 (0.060, 0.38)

Erlotinib vs Chemotherapy

1		←————————→	7.3e−18 (3.4e−43, 1.6e+08)
22		←————————→	6.6e+11 (6.4e−06, 6.9e+28)
27		—o—	0.58 (0.077, 4.3)
51		—o—	4.0 (0.66, 24.)
68		—o—	0.69 (0.30, 1.6)
69		←————————→	4.0e+10 (9.4e−06, 1.7e+26)
Pooled (pair−wise)	47.4%	—■—	1.3 (0.55, 3.6)
Indirect (back−calculated)		····o····	0.50 (0.22, 1.2)
Pooled (network)	38.4%	—■—	0.76 (0.40, 1.4)

0.03   1   30

Study	I^2	Odds Ratio (95% CrI)

Gefitinib vs Chemotherapy

13		2.5e−18 (4.9e−43, 1.3e+07)
73		7.0e−18 (2.9e−43, 1.7e+08)
75		7.4e−18 (3.5e−43, 1.6e+08)
76		0.97 (0.22, 4.2)
77		8.8e−18 (2.9e−43, 2.6e+08)
Pooled (pair−wise)	60.0%	0.25 (0.047, 0.85)
Indirect (back−calculated)		0.70 (0.30, 1.7)
Pooled (network)	37.2%	0.54 (0.25, 1.1)

Osimertinib vs Chemotherapy

42		0.70 (0.25, 2.0)
Pooled (pair−wise)		0.69 (0.15, 3.4)
Indirect (back−calculated)		1.1 (0.35, 3.2)
Pooled (network)	0.0%	0.92 (0.36, 2.2)

Erlotinib vs Dacomitinib

45		6.1 (0.41, 91.)
59		1.4 (0.55, 3.3)
Pooled (pair−wise)	13.3%	1.8 (0.57, 7.1)
Indirect (back−calculated)		0.91 (0.30, 2.8)
Pooled (network)	0.0%	1.2 (0.53, 2.8)

Gefitinib vs Dacomitinib

43		0.37 (0.019, 7.3)
Pooled (pair−wise)		0.42 (0.0080, 7.1)
Indirect (back−calculated)		0.95 (0.34, 2.7)
Pooled (network)	0.0%	0.88 (0.32, 2.3)

0.03 1 30

Study	I^2		Odds Ratio (95% CrI)

Placebo vs Dacomitinib

r6		0.55 (0.17, 1.8)
Pooled (pair−wise)		0.56 (0.099, 2.8)
Indirect (back−calculated)		1.2 (0.40, 3.3)
Pooled (network)	0.0%	0.93 (0.38, 2.2)

Erlotinib vs DHFRi

r18		0.96 (0.028, 33.)
Pooled (pair−wise)		1.0 (0.021, 64.)
Indirect (back−calculated)		NA
Pooled (network)		1.2 (0.026, 43.)

Gefitinib vs Erlotinib_ERi

72		0.45 (0.10, 2.0)
Pooled (pair−wise)		0.46 (0.066, 3.0)
Indirect (back−calculated)		NA
Pooled (network)		0.32 (0.093, 1.0)

Gefitinib_ERi vs Erlotinib_ERi

72		1.6 (0.64, 4.1)
Pooled (pair−wise)		1.6 (0.36, 7.3)
Indirect (back−calculated)		NA
Pooled (network)		1.6 (0.52, 5.3)

antiangio vs Erlotinib_antiangio

37		4.8 (0.65, 35.)
Pooled (pair−wise)		4.6 (0.45, 48.)
Indirect (back−calculated)		1.3 (0.45, 3.9)
Pooled (network)	20.2%	1.6 (0.70, 4.9)

0.03   1   30

Study	I^2		Odds Ratio (95% CrI)
Erlotinib_Autophagyi vs Erlotinib			
r15			3.9e−18 (4.4e−43, 3.4e+07)
Pooled (pair−wise)			1.9e−13 (1.5e−39, 0.11)
Indirect (back−calculated)			NA
Pooled (network)			1.3e−19 (4.7e−50, 0.047)
Erlotinib_chemotherapy vs Erlotinib			
61			1.3 (0.035, 45.)
67			0.33 (0.12, 0.93)
71			6.3e+11 (8.6e−06, 4.6e+28)
Pooled (pair−wise)	46.4%		0.65 (0.20, 2.8)
Indirect (back−calculated)			NA
Pooled (network)	42.9%		0.62 (0.21, 2.0)
Erlotinib_COX2i vs Erlotinib			
17			9.8e−18 (4.2e−43, 2.3e+08)
Pooled (pair−wise)			3.4e−19 (9.1e−44, 0.016)
Indirect (back−calculated)			NA
Pooled (network)			2.8e−11 (2.8e−26, 0.16)
Erlotinib_ERi vs Erlotinib			
72			3.6 (0.51, 25.)
Pooled (pair−wise)			3.5 (0.38, 36.)
Indirect (back−calculated)			NA
Pooled (network)			2.2 (0.67, 7.4)
Erlotinib_HER3i vs Erlotinib			
62			0.68 (0.13, 3.5)
Pooled (pair−wise)			0.69 (0.10, 5.7)
Indirect (back−calculated)			NA
Pooled (network)			0.65 (0.10, 4.5)

0.03   1   30

Study	I^2		Odds Ratio (95% CrI)

Erlotinib_HGFi vs Erlotinib

56			0.93 (0.027, 32.)
Pooled (pair−wise)			0.95 (0.031, 57.)
Indirect (back−calculated)			NA
Pooled (network)			0.92 (0.033, 36.)

Erlotinib_IGF_1Ri vs Erlotinib

44			2.6 (0.86, 8.0)
66			4.4e+12 (1.9e−09, 1.0e+34)
9			3.8e+07 (0.00011, 1.3e+19)
Pooled (pair−wise)	53.9%		5.6 (1.8, 30.)
Indirect (back−calculated)			NA
Pooled (network)	50.5%		5.3 (1.8, 20.)

Erlotinib_METi vs Erlotinib

12			1.1 (0.61, 1.9)
32			1.0 (0.026, 38.)
39			0.52 (0.14, 2.0)
7			1.0 (0.58, 1.8)
79			7.2e−18 (3.4e−43, 1.5e+08)
Pooled (pair−wise)	0.0%		0.88 (0.37, 1.8)
Indirect (back−calculated)			NA
Pooled (network)	0.0%		0.92 (0.46, 1.6)

Erlotinib_MMPi vs Erlotinib

21			0.37 (0.083, 1.6)
Pooled (pair−wise)			0.38 (0.048, 2.3)
Indirect (back−calculated)			NA
Pooled (network)			0.37 (0.062, 1.9)

0.03   1   30

Study	I^2		Odds Ratio (95% CrI)

Erlotinib_antiangio vs Erlotinib

15			1.9 (0.96, 3.8)
16			1.0 (0.44, 2.4)
19			4.2 (0.29, 62.)
2			1.0 (0.23, 4.6)
24			0.27 (0.045, 1.6)
25			1.2 (0.71, 2.0)
33			0.093 (0.0064, 1.3)
34			1.9 (1.1, 3.4)
35			2.8e+12 (9.6e−05, 8.4e+28)
36			1.0 (0.17, 6.3)
37			1.0 (0.022, 47.)
41			8.3e−18 (3.8e−43, 1.8e+08)
Pooled (pair−wise)	30.5%		1.2 (0.66, 1.9)
Indirect (back−calculated)			NA
Pooled (network)	30.6%		1.2 (0.73, 1.7)

Gefitinib vs Erlotinib

72			1.6 (0.13, 19.)
Pooled (pair−wise)			1.6 (0.11, 25.)
Indirect (back−calculated)			0.68 (0.32, 1.4)
Pooled (network)	0.0%		0.72 (0.34, 1.4)

Gefitinib_ERi vs Erlotinib

72			5.9 (1.2, 29.)
Pooled (pair−wise)			6.0 (0.81, 43.)
Indirect (back−calculated)			NA
Pooled (network)			3.6 (1.2, 12.)

0.03   1   30

Study	I^2		Odds Ratio (95% CrI)
Placebo vs Erlotinib			
30			0.56 (0.12, 2.7)
46			1.8 (0.73, 4.5)
58			2.6 (0.59, 11.)
Pooled (pair−wise)	9.7%		1.5 (0.54, 3.7)
Indirect (back−calculated)			0.46 (0.20, 1.1)
Pooled (network)	61.0%		0.76 (0.39, 1.4)
Rociletinib vs Erlotinib			
53			0.99 (0.027, 36.)
Pooled (pair−wise)			0.97 (0.017, 47.)
Indirect (back−calculated)			NA
Pooled (network)			0.96 (0.0046, 94.)
antiangio vs Erlotinib			
28			1.3 (0.67, 2.6)
37			4.9 (0.66, 37.)
Pooled (pair−wise)	37.4%		1.7 (0.59, 6.2)
Indirect (back−calculated)			NA
Pooled (network)	51.2%		2.0 (0.86, 5.1)
Osimertinib vs Gefitinib_Erlotinib			
31			2.8 (0.96, 8.3)
Pooled (pair−wise)			2.8 (0.58, 15.)
Indirect (back−calculated)			NA
Pooled (network)			2.8 (0.75, 12.)

0.03 1 30

Study	I^2		Odds Ratio (95% CrI)

Gefitinib_chemotherapy vs Gefitinib

14			1.0 (0.31, 3.4)
23			8.4e+14 (0.00016, 4.5e+33)
49			8.2 (0.60, 1.1e+02)
74			4.1 (0.27, 64.)
Pooled (pair-wise)	44.5%		2.6 (0.93, 9.1)
Indirect (back-calculated)			NA
Pooled (network)	42.9%		2.5 (0.98, 7.1)

Gefitinib_ERi vs Gefitinib

72			3.7 (1.1, 12.)
Pooled (pair-wise)			3.7 (0.68, 19.)
Indirect (back-calculated)			NA
Pooled (network)			5.1 (1.7, 17.)

Lazertinib vs Gefitinib

r17			2.6 (1.2, 5.6)
Pooled (pair-wise)			2.6 (0.62, 11.)
Indirect (back-calculated)			2.2 (0.67, 7.4)
Pooled (network)	0.0%		2.4 (0.94, 5.9)

Placebo vs Gefitinib

64			0.57 (0.12, 2.7)
r5			1.1e−17 (8.0e−43, 1.4e+08)
Pooled (pair-wise)	43.9%		0.44 (0.064, 2.3)
Indirect (back-calculated)			1.3 (0.55, 3.0)
Pooled (network)	22.9%		1.1 (0.49, 2.3)

0.03   1   30

Study	I^2		Odds Ratio (95% CrI)

Osimertinib vs Lazertinib

r1			0.76 (0.33, 1.7)
Pooled (pair−wise)			0.76 (0.18, 3.3)
Indirect (back−calculated)			0.70 (0.24, 2.0)
Pooled (network)	0.0%		0.72 (0.31, 1.7)

Osimertinib_chemotherapy vs Osimertinib

r16			2.1 (0.82, 5.5)
Pooled (pair−wise)			2.1 (0.47, 9.9)
Indirect (back−calculated)			NA
Pooled (network)			2.1 (0.62, 7.6)

Osimertinib_antiangio vs Osimertinib

8			0.43 (0.063, 2.9)
Pooled (pair−wise)			0.44 (0.038, 3.6)
Indirect (back−calculated)			NA
Pooled (network)			0.44 (0.048, 2.9)

PD_L1i vs Osimertinib

52			0.50 (0.023, 11.)
Pooled (pair−wise)			0.56 (0.016, 11.)
Indirect (back−calculated)			NA
Pooled (network)			0.55 (0.017, 8.8)

Placebo vs Osimertinib

10			0.45 (0.13, 1.6)
r19			0.73 (0.038, 14.)
Pooled (pair−wise)	0.0%		0.56 (0.12, 2.4)
Indirect (back−calculated)			0.67 (0.22, 2.0)
Pooled (network)	0.0%		0.63 (0.26, 1.5)

0.03   1   30